Skip to main content
Erschienen in: Current Treatment Options in Gastroenterology 2/2022

19.03.2022 | Genetics in Gastroenterology Practice (BW Katona, Section Editor)

Incidental Young-Onset Adenomas: Sporadic Findings or Harbingers of Increased Colon Cancer Risk?

verfasst von: Yasmin Kamal, PhD, Gregory Idos, MD, MS

Erschienen in: Current Treatment Options in Gastroenterology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

We aimed to determine whether young-onset adenomas increased the risk for colorectal cancer by determining the adenoma prevalence, risk factors associated with young-onset adenomas, as well as the need for surveillance colonoscopies in the young-adult population (age < 50).

Recent findings

By examining multiple meta-analyses and systematic review studies, we determined that while adenoma rates are lower in young adults (age < 45) compared to those > age 50, subsets of young adults are at higher risk of adenoma formation and therefore may have increased colorectal cancer risk. Therefore, surveillance colonoscopy may be beneficial for patients aged 40–49 years of age to reduce colorectal cancer risk, particularly in young-adult patients presenting with concerning symptoms, such as bright red blood per rectum, those found to have high-risk advanced adenomas, and those with risk factors associated with higher adenoma detection rates including diabetes, male gender, and metabolic syndrome.

Summary

Young adults found to have adenomas may warrant both close surveillance with colonoscopy as well as hereditary cancer risk assessment and genetic testing to identify underlying hereditary cancer syndromes.
Literatur
1.
Zurück zum Zitat You YN, Lee LD, Deschner BW, Shibata D. Colorectal cancer in the adolescent and young adult population. J Oncol Pract. 2020;16:19–27.CrossRef You YN, Lee LD, Deschner BW, Shibata D. Colorectal cancer in the adolescent and young adult population. J Oncol Pract. 2020;16:19–27.CrossRef
3.
Zurück zum Zitat Butterly LF, Siegel RL, Fedewa S, Robinson CM, Jemal A, Anderson JC. Colonoscopy outcomes in average-risk screening equivalent young adults: data from the New Hampshire colonoscopy registry. Am J Gastroenterol. 2021;116:171–9.CrossRef Butterly LF, Siegel RL, Fedewa S, Robinson CM, Jemal A, Anderson JC. Colonoscopy outcomes in average-risk screening equivalent young adults: data from the New Hampshire colonoscopy registry. Am J Gastroenterol. 2021;116:171–9.CrossRef
4.
Zurück zum Zitat Rundle A, Lebwohl B, Vogel R, Levine S, Neugut A. Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology. 2008;134:1311–5.CrossRef Rundle A, Lebwohl B, Vogel R, Levine S, Neugut A. Colonoscopic screening in average-risk individuals ages 40 to 49 vs 50 to 59 years. Gastroenterology. 2008;134:1311–5.CrossRef
5.
Zurück zum Zitat Karsenti D, Tharsis G, Burtin P, Venezia F, Tordjman G, Gillet A, Samama J, Nahon-Uzan K, Cattan P, Cavicchi M. Adenoma and advanced neoplasia detection rates increase from 45 years of age. World J Gastroenterol. 2019;25:447–56.CrossRef Karsenti D, Tharsis G, Burtin P, Venezia F, Tordjman G, Gillet A, Samama J, Nahon-Uzan K, Cattan P, Cavicchi M. Adenoma and advanced neoplasia detection rates increase from 45 years of age. World J Gastroenterol. 2019;25:447–56.CrossRef
6.
Zurück zum Zitat Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki M, Butruk E. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863–72.CrossRef Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki M, Butruk E. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863–72.CrossRef
7.
Zurück zum Zitat Chang L, Wu M, Tu C, Lee Y, Shun C, Chiu H. Metabolic syndrome and smoking may justify earlier colorectal cancer screening in men. Gastrointest Endosc. 2014;79:961–9.CrossRef Chang L, Wu M, Tu C, Lee Y, Shun C, Chiu H. Metabolic syndrome and smoking may justify earlier colorectal cancer screening in men. Gastrointest Endosc. 2014;79:961–9.CrossRef
9.
Zurück zum Zitat Enwerem N, Cho MY, Demb J, Earles A, Heskett KM, Liu L, Singh S, Gupta S. Systematic review of prevalence, risk factors, and risk for metachronous advanced neoplasia in patients with young-onset colorectal adenoma. Clin Gastroenterol Hepatol. 2021;19:680-689.e12.CrossRef Enwerem N, Cho MY, Demb J, Earles A, Heskett KM, Liu L, Singh S, Gupta S. Systematic review of prevalence, risk factors, and risk for metachronous advanced neoplasia in patients with young-onset colorectal adenoma. Clin Gastroenterol Hepatol. 2021;19:680-689.e12.CrossRef
10.
Zurück zum Zitat Lu R, Kassim T, Dave D, Klair JS, Ashfaq M, Chandra S, Murali AR. Diagnostic yield of colonoscopy in young adults with lower gastrointestinal symptoms in a multicenter midwest cohort. Dig Dis. 2020;38:484–9.CrossRef Lu R, Kassim T, Dave D, Klair JS, Ashfaq M, Chandra S, Murali AR. Diagnostic yield of colonoscopy in young adults with lower gastrointestinal symptoms in a multicenter midwest cohort. Dig Dis. 2020;38:484–9.CrossRef
11.
Zurück zum Zitat Stratmann K, Czerwinska K, Filmann N, Tacke W, Weber C, Bock H, Blumenstein I. Prevalence of colorectal cancer and its precursor lesions in symptomatic patients under 55 years of age undergoing total colonoscopy: results of a large retrospective, multicenter, controlled endoscopy study. Int J Colorectal Dis. 2021;36:1695–700.CrossRef Stratmann K, Czerwinska K, Filmann N, Tacke W, Weber C, Bock H, Blumenstein I. Prevalence of colorectal cancer and its precursor lesions in symptomatic patients under 55 years of age undergoing total colonoscopy: results of a large retrospective, multicenter, controlled endoscopy study. Int J Colorectal Dis. 2021;36:1695–700.CrossRef
12.
Zurück zum Zitat Rex D, Ahnen D, Baron J, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–29.CrossRef Rex D, Ahnen D, Baron J, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–29.CrossRef
13.
Zurück zum Zitat Breau G, Ellis U. Risk factors associated with young-onset colorectal adenomas and cancer: a systematic review and meta-analysis of observational research. Cancer Control. 2020;27:1073274820976670.CrossRef Breau G, Ellis U. Risk factors associated with young-onset colorectal adenomas and cancer: a systematic review and meta-analysis of observational research. Cancer Control. 2020;27:1073274820976670.CrossRef
14.
Zurück zum Zitat Wu H, Zhang J, Zhou B. Metabolic syndrome and colorectal adenoma risk: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021;45:101749.CrossRef Wu H, Zhang J, Zhou B. Metabolic syndrome and colorectal adenoma risk: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2021;45:101749.CrossRef
15.
Zurück zum Zitat Imperiale TF, Abhyankar PR, Stump TE, Emmett TW. Prevalence of advanced, precancerous colorectal neoplasms in Black and White populations: a systematic review and meta-analysis. Gastroenterology. 2018;155:1776-1786.e1.CrossRef Imperiale TF, Abhyankar PR, Stump TE, Emmett TW. Prevalence of advanced, precancerous colorectal neoplasms in Black and White populations: a systematic review and meta-analysis. Gastroenterology. 2018;155:1776-1786.e1.CrossRef
16.
Zurück zum Zitat Lieberman DA, Williams JL, Holub JL, Morris CD, Logan JR, Eisen GM, Carney P. Race, ethnicity, and sex affect risk for polyps greater than 9 mm in average-risk individuals. Gastroenterology. 2014;147:351.CrossRef Lieberman DA, Williams JL, Holub JL, Morris CD, Logan JR, Eisen GM, Carney P. Race, ethnicity, and sex affect risk for polyps greater than 9 mm in average-risk individuals. Gastroenterology. 2014;147:351.CrossRef
17.
Zurück zum Zitat Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017;35:1086–95.CrossRef Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017;35:1086–95.CrossRef
18.
Zurück zum Zitat Giardiello F, Allen J, Axilbund J, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2014;147:502–26.CrossRef Giardiello F, Allen J, Axilbund J, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2014;147:502–26.CrossRef
19.
Zurück zum Zitat Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507–17.CrossRef Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507–17.CrossRef
20.
Zurück zum Zitat Weiss JM, Gupta S, Burke CA, Axell L, Chen LM, Chung DC, Clayback KM, Dallas S, Felder S, Gbolahan O, Giardiello FM, Grady W, Hall MJ, Hampel H, Hodan R, Idos G, Kanth P, Katona B, Lamps L, ... Campbell M. Genetic/familial high-risk assessment: Colorectal, version 1.2021 featured updates to the NCCN Guidelines. JNCCN J Nat Comp Cancer Net. 2021;19(10):1122–1132. https://doi.org/10.1164/jnccn.2021.0048 Weiss JM, Gupta S, Burke CA, Axell L, Chen LM, Chung DC, Clayback KM, Dallas S, Felder S, Gbolahan O, Giardiello FM, Grady W, Hall MJ, Hampel H, Hodan R, Idos G, Kanth P, Katona B, Lamps L, ... Campbell M. Genetic/familial high-risk assessment: Colorectal, version 1.2021 featured updates to the NCCN Guidelines. JNCCN J Nat Comp Cancer Net. 2021;19(10):1122–1132. https://​doi.​org/​10.​1164/​jnccn.​2021.​0048
21.
Zurück zum Zitat Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Mol Diagn. 2017;19:187–225.CrossRef Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Mol Diagn. 2017;19:187–225.CrossRef
22.
Zurück zum Zitat Berg AO, Armstrong K, Botkin J, et al. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11:35–41.CrossRef Berg AO, Armstrong K, Botkin J, et al. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11:35–41.CrossRef
23.
Zurück zum Zitat Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62.CrossRef Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62.CrossRef
24.
Zurück zum Zitat Basterra M, Gomez M, Mercado MDR, Irisarri R, Amorena E, Arrospide A, Montes M, Aisa G, Cambra KI, Urman J. Prevalence of altered mismatch repair protein nuclear expression detected by immunohistochemistry on adenomas with high-grade dysplasia and features associated with this risk in a population-based study. Gastroenterol Hepatol. 2016;39:500–7.CrossRef Basterra M, Gomez M, Mercado MDR, Irisarri R, Amorena E, Arrospide A, Montes M, Aisa G, Cambra KI, Urman J. Prevalence of altered mismatch repair protein nuclear expression detected by immunohistochemistry on adenomas with high-grade dysplasia and features associated with this risk in a population-based study. Gastroenterol Hepatol. 2016;39:500–7.CrossRef
25.
Zurück zum Zitat Velayos F, Allen B, Conrad P, Gum J, Kakar S, Chung D, Truta B, Sleisenger M, Kim Y, Terdiman J. Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines. Am J Gastroenterol. 2005;100:1143–9.CrossRef Velayos F, Allen B, Conrad P, Gum J, Kakar S, Chung D, Truta B, Sleisenger M, Kim Y, Terdiman J. Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines. Am J Gastroenterol. 2005;100:1143–9.CrossRef
26.
Zurück zum Zitat Dabir P, Bruggeling C, van der Post R, Dutilh B, Hoogerbrugge N, Ligtenberg MJL, Boleij A, Nagtegaal I. Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis. Eur J Hum Genet. 2020;28:277–86.CrossRef Dabir P, Bruggeling C, van der Post R, Dutilh B, Hoogerbrugge N, Ligtenberg MJL, Boleij A, Nagtegaal I. Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis. Eur J Hum Genet. 2020;28:277–86.CrossRef
27.
Zurück zum Zitat Idos G, Gupta S. When should patients undergo genetic testing for hereditary colon cancer syndromes? Clin Gastroenterol Hepatol. 2018;16:181–3.CrossRef Idos G, Gupta S. When should patients undergo genetic testing for hereditary colon cancer syndromes? Clin Gastroenterol Hepatol. 2018;16:181–3.CrossRef
28.
Zurück zum Zitat Shaukat A, Kahi C, Burke C, Rabeneck L, Sauer B, Rex D. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116:458–79.CrossRef Shaukat A, Kahi C, Burke C, Rabeneck L, Sauer B, Rex D. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116:458–79.CrossRef
29.
Zurück zum Zitat Gupta S, Lieberman D, Anderson J, Burke C, Dominitz J, Kaltenbach T, Robertson D, Shaukat A, Syngal S, Rex D. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastrointest Endosc. 2020;91:463-485.e5.CrossRef Gupta S, Lieberman D, Anderson J, Burke C, Dominitz J, Kaltenbach T, Robertson D, Shaukat A, Syngal S, Rex D. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastrointest Endosc. 2020;91:463-485.e5.CrossRef
Metadaten
Titel
Incidental Young-Onset Adenomas: Sporadic Findings or Harbingers of Increased Colon Cancer Risk?
verfasst von
Yasmin Kamal, PhD
Gregory Idos, MD, MS
Publikationsdatum
19.03.2022
Verlag
Springer US
Erschienen in
Current Treatment Options in Gastroenterology / Ausgabe 2/2022
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-022-00375-0

Weitere Artikel der Ausgabe 2/2022

Current Treatment Options in Gastroenterology 2/2022 Zur Ausgabe

Endoscopy (P Siersema, Section Editor)

Prevention of Duodenoscope-Associated Infections

Geriatrics (A Afzali and S Katz, Section Editors)

Endoscopic Bariatric Procedures and the Elderly

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.